A novel oncolytic HSV co-expressing IL-12 and anti-PD-1 for glioblastoma

被引：0
|
作者：
Ayele, Kalkidan [1 ]
Feng, Xiaodong [1 ]
Saha, Dipongkor [1 ]
机构：
[1] Calif Northstate Univ, Coll Pharm, Dept Pharmaceut & Biomed Sci, Elk Grove, CA 95757 USA
来源：
MOLECULAR THERAPY ONCOLOGY | 2024年 / 32卷 / 02期
关键词：
D O I：
10.1016/j.omton.2024.200810
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Intravenous (IV) infusion of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, as monotherapy in advanced solid tumors: Preliminary results from an ongoing phase 1/2a study
    Niu, Jiaxin
    Barve, Minal A.
    Spira, Alexander I.
    Edenfield, William Jeffery
    Pang, Weijia
    Fu, Wenmin
    Lu, Yingxin
    McKean, Meredith
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] ENHANCED EFFICACY OF ONCOLYTIC HERPES SIMPLEX VIRUS TYPE 1 (HSV-1) ARMED WITH IL-12 IN BLADDER CANCER MODELS
    Fukuhara, Hiroshi
    Hou, Jiangang
    Tsurumaki, Yuzuri
    Homma, Yukio
    Ino, Yasushi
    Todo, Tomoki
    JOURNAL OF UROLOGY, 2010, 183 (04): : E304 - E304
  • [43] Novel therapeutic strategy with anti-PD-1 antibody and telomerase-specific oncolytic virotherapy in osteosarcoma
    Mochizuki, Yusuke
    Tazawa, Hiroshi
    Demiya, Koji
    Komatsubara, Tadashi
    Sugiu, Kazuhisa
    Hasei, Joe
    Kunisada, Toshiyuki
    Urata, Yasuo
    Ozaki, Toshifumi
    Fujiwara, Toshiyoshi
    CANCER SCIENCE, 2018, 109 : 1167 - 1167
  • [44] ENHANCED EFFICACY OF ONCOLYTIC HERPES SIMPLEX VIRUS (HSV-1) ARMED WITH IL-12 RENAL CELL CARCINOMA MODELS
    Fukuhara, Hiroshi
    Tsurumaki, Yuzuri
    Ino, Yasushi
    Todo, Tomoki
    Honma, Yukio
    JOURNAL OF UROLOGY, 2009, 181 (04): : 153 - 153
  • [45] Evaluation of controlled IL-12 in combination with a PD-1 inhibitor in subjects with recurrent glioblastoma.
    Chiocca, E. Antonio
    Lukas, Rimas Vincas
    Rao, Ganesh
    Barrett, John A.
    Buck, Jill Y.
    Demars, Nathan
    Smith, Amy
    Miao, John
    Zhou, Qiang
    Gelb, Arnold Bruce
    Cooper, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [46] Intratumoral plasmid IL-12 enhanced the systemic anti-tumor effect of anti-PD-1 antibody in triple-negative breast cancer.
    Nagata, Hiroshi
    Osada, Takuya
    Crosby, Erika J.
    Canton, David A.
    Twitty, Chris G.
    Lyerly, H. Kim
    CANCER RESEARCH, 2021, 81 (13)
  • [47] Anti-PD-1 antibody enhances antitumor efficacy of oncolytic HSV-1 G47 Δ in a mouse lung cancer model
    Sakata, Yoshinori
    Ino, Yasushi
    Iwai, Miwako
    Ikeda, Norihiko
    Todo, Tomoki
    CANCER SCIENCE, 2018, 109 : 1185 - 1185
  • [48] Wnt inhibition improves the efficacy of anti-PD-1 therapy in glioblastoma
    Krishnan, Shanmugarajan
    Lee, Somin
    Amoozgar, Zohreh
    Subudhi, Sonu
    Kumar, Ashwin S.
    Posada, Jessica
    Lindeman, Neal
    Lei, Pinji
    Duquette, Mark
    Huang, Peigen
    Andersson, Patrik
    Datta, Meenal
    Munn, Lance L.
    Fukumura, Dai
    Jain, Rakesh K.
    CANCER IMMUNOLOGY RESEARCH, 2024, 12 (10)
  • [49] EFFECT OF ANTI-PD-1 THERAPY COMBINATION ON TEMOZOLOMIDE IN MOUSE GLIOBLASTOMA
    Park, Junseong
    Kim, Chang Gon
    Shim, Jin-Kyong
    Lee, Jae Eun
    Chang, Jong Hee
    Shin, Eui-Cheol
    Kang, Seok-Gu
    NEURO-ONCOLOGY, 2017, 19 : 116 - 116
  • [50] Combination treatment with recombinant murine IL-12 and anti-PD-1 antibody enhanced anti-tumor efficacy through the activation of cytotoxic T cell response
    Yang, Yeng-Jey
    Tsou, Pei-Yi
    Chou, Shiuh-Dih
    Lee, Meng-Na
    Chen, San-Chi
    CANCER RESEARCH, 2023, 83 (07)
12345